Jian Jin laboratory has three main research topics: (1) discover selective inhibitors of histone methyltransferases (HMTs), (2) discover biased ligands of G protein-coupled receptors …

Dr. Jian Jin is currently the Mount Sinai Endowed Professor in Therapeutics Discovery and Director of the Mount Sinai Center for Therapeutics Discovery at Icahn School of Medicine at …

Dr. Jin’s lab is a pioneer and leader in discovering and characterizing first-in-class small-molecule degraders (also known as proteolysis targeting chimeras (PROTACs)) that target oncogenic …

Jin, J*., Wen, H.*, Science Advances, “A potent and selective ENL degrader suppresses oncogenic gene expression and leukemia progression”. 2024 Aug 30;10 (35).eado1432.

The Jin lab has taken a systematic approach to target HMTs for over a decade. By targeting the HMT substrate binding groove, cofactor binding site, and allosteric binding sites, the Jin lab …

Dr. Jian Jin is currently the Mount Sinai Endowed Professor in Therapeutics Discovery and Director of the Mount Sinai Center for Therapeutics Discovery at Icahn School of Medicine at …

Our Novel Degraders Targeting Oncogenic Proteins: MS4077 & MS4078: ALK degrader (PMID: 29627725) MS432: MEK1/2 degrader (PMID:31730343) MS1943: EZH2 degrader …

Group Pictures Department Retreat at NYBG, group picture 2024 Holiday Celebration, December 2024 Holiday Celebration, December 2023 Group Picture, September 2023 Celebration …

The research team led by Dr. Jian Jin discovered MS147, the first small-molecule degrader of polycomb repressive complex 1 (PRC1) components, BMI1 and RING1B, using the bridged …

The research team led by Dr. Jian Jin discovered MS147, the first small-molecule degrader of polycomb repressive complex 1 (PRC1) components, BMI1 and RING1B, using the bridged …